Search
Phenol
go.drugbank.com/drugs/DB03255ApprovedInvestigationalPhenol has been used to disinfect skin and to relieve itching. Phenol is also used as an oral analgesic or anesthetic in products such as Chloraseptic to treat pharyngitis. … Additionally, phenol and its related compounds are used in surgical ingrown toenail treatment, a process termed phenolization.
Mixtures: Au Kah Chuen Skin Lotion, DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİCategories: Compounds used in a research, industrial, or household settingBaculoviral IAP repeat-containing protein 5
go.drugbank.com/bio_entities/BE0003408TargetHumansIsoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform (PubMed:10626797) … Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis (PubMed:16322459).
Polypeptides: Baculoviral IAP repeat-containing protein 5Baculoviral IAP repeat-containing protein 7
go.drugbank.com/bio_entities/BE0010707TargetHumansApoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control (PubMed:11024045, PubMed:11084335, PubMed:11162435, PubMed:16729033, PubM...
Polypeptides: Baculoviral IAP repeat-containing protein 7Conivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
Products: Vaprisol Dextrose In Plastic ContainerSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[L45300,L45315] In September 2024, it was granted full approval for an expanded indication. … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub
Categories: Agents Acting on the Renin-Angiotensin SystemHydroxyethyl cellulose
go.drugbank.com/drugs/DB11602ApprovedIt is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic … It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature.
Salts: Hydroxyethyl cellulose (2000 MPa.s at 1%), Hydroxyethyl cellulose (280 MPa.s at 2%)Categories: Compounds used in a research, industrial, or household settingAggrecan core protein
go.drugbank.com/bio_entities/BE0004104TargetHumansThis proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region
Polypeptides: Aggrecan core proteinSynonyms: Cartilage-specific proteoglycan core protein, Chondroitin sulfate proteoglycan core protein 1Foslevodopa
go.drugbank.com/drugs/DB16683ApprovedFoslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants
Mixtures: Produodopa 240 mg/ml + 12 mg/ml InfusionslösungTofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46108] Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented. … [L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPPegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.